Delcath Systems Inc
Delcath Systems Inc (DCTH) Covered Calls
Delcath Systems Inc trades in the Medical Devices industry with an IV Rank of 20.24%, low versus the past year. DCTH's highest covered call setup is the $25.00 strike expiring Dec 18, 2026, sorted by theoretical annualized return. It's 25.82% out of the money with 32 days to expiration, a 26.32% return until expiration, and a 300.22% theoretical annualized return. Across the setups shown, annualized returns run from 27.65% to 300.22% at strikes between $20.00 and $25.00, with 4 to 186 days to expiration, as of Nov 16, 2026.
Read more
Running DCTH covered calls helps you generate income from Delcath Systems Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best DCTH covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If DCTH stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling DCTH covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given DCTH covered call is worth writing.
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe.
| 2026-12-18 | 32 | 25.00 | 25.82 | 0.10 | 0.55 | 523.00 | 26.32 | 300.22 | -0.50 | +0.16 | 55 | 0.45 |
| 2026-11-20 | 4 | 20.00 | 0.65 | 0.35 | 0.80 | 48.00 | 2.42 | 220.43 | -1.76 | +0.49 | 181 | 0.45 |
| 2026-12-18 | 32 | 22.50 | 13.24 | 0.25 | 1.75 | 288.00 | 14.49 | 165.32 | -1.26 | +0.35 | 91 | 1.50 |
| 2027-02-19 | 95 | 25.00 | 25.82 | 0.70 | 1.55 | 583.00 | 29.34 | 112.73 | -3.52 | +0.31 | 135 | 0.85 |
| 2026-12-18 | 32 | 20.00 | 0.65 | 1.25 | 1.85 | 138.00 | 6.95 | 79.22 | -6.29 | +0.53 | 27 | 0.60 |
| 2027-05-21 | 186 | 25.00 | 25.82 | 1.65 | 2.75 | 678.00 | 34.12 | 66.96 | -8.30 | +0.42 | 7 | 1.10 |
| 2027-02-19 | 95 | 22.50 | 13.24 | 0.10 | 2.35 | 273.00 | 13.74 | 52.79 | -0.50 | +0.38 | 36 | 2.25 |
| 2027-05-21 | 186 | 22.50 | 13.24 | 2.15 | 4.20 | 478.00 | 24.06 | 47.21 | -10.82 | +0.52 | 12 | 2.05 |
| 2027-05-21 | 186 | 20.00 | 0.65 | 3.60 | 5.00 | 373.00 | 18.77 | 36.84 | -18.12 | +0.62 | 21 | 1.40 |
| 2027-02-19 | 95 | 20.00 | 0.65 | 1.30 | 4.10 | 143.00 | 7.20 | 27.65 | -6.54 | +0.57 | 108 | 2.80 |
As of Nov 16, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryMedical Devices
- SectorHealthcare
- IV Rank20.24% Low
- Market cap (M$)654
- 52 weeks high-16.53%
- 52 weeks low121.58%
- Analyst recommendationStrong Buy
1.00 - Target price$28.33
50.77% above the current stock price - Dividend—
- Payout ratio0.00%
- Earnings date2026-11-09
- P/E121.30
- Future P/E107.03
- EPS (ttm)0.15
- EPS growth next 5 years82.89%
As of Nov 20, 2026